Skip to main content
BKYI logo

BKYI · Bio Key International Inc · Documents

Track BKYI — free
$2.10 -0.02 (-1.17%) Play latest call Q3 2026 earnings call transcript
Market Cap
$4.31M
Shares
2.04M
Volume · Nov 16 10.06K Avg daily vol (3M) 5.36M

The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →

Annual report FY2025 Revenue $5.94M down 14.3% 10-K filed Jun 12, 2026 Quarterly report New FY2026 Q3 Revenue $1.48M down 4.3% 10-Q filed Nov 13, 2026 Latest results New Software license fees grew 39%, gross margin reached 90% 8-K filed Nov 13, 2026 Earnings call New Q3 2026 earnings call Held Nov 13, 2026
2026
Nov 13
Earnings call
License revenue rose 39% as gross margin reached 90%

BioKey reported third-quarter license fee revenue of $1.28 million, up 39%, lifting gross margin to 90%. It retired remaining note debt, won a Central Bank of Jordan initiative, and targets profitability with roughly $1.2 million in first-quarter license renewals.

5 source passages
License fee revenue grew 39% year over year, and that high margin recurring revenue lifted our gross margin to 90% from 77% a year ago, and helped reduce our operating loss by 8%. Total revenue for our Q326 was $1.48 million compared to $1.55 million in Q325. License fee revenue increased 39% to $1.28 million, representing 86% of total revenue versus 59% a year ago. In the third quarter, the Central Bank of Jordan selected BioKey for a national biometric authentication initiative. During the quarter, we retired the remaining balance of our note payable, leaving us free of our note debt. We expect roughly $1.2 million in annual license fee renewals in the first quarter alone, and we are targeting profitability as we approach that time frame. Open the document at this passage
Nov 13
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Going-concern doubt persists despite revenue growth

BIO-KEY INTERNATIONAL, INC. reported nine-month revenue of 5,548,305, net loss of 1,667,972 and operating cash outflow of 2,634,682. Management said substantial doubt exists about its ability to continue as a going concern.

Revenue $1.48M ▼ 4.3% Net loss $886.08K
Read from the first part of this long document
5 source passages
BIO-KEY INTERNATIONAL, INC. AND SUBSIDIARIES Total revenues | 1,482,781 | 1,549,706 | 5,548,305 | 4,853,772 Net loss | (1,667,972) | (2,868,790) Net cash used in operating activities | (2,634,682) | (2,838,088) The history of losses, the negative cash flow from operations, and the dependence by the Company on its ability to obtain additional financing to fund its operations after the current cash resources are exhausted raise doubt about the Company's ability to continue as a going concern. Open the document at this passage
Nov 13
Current report 8-K
Software license fees grew 39%, gross margin reached 90%

BIO-key reported Q3’26 license fee revenue growth of 39%, gross margin improvement to 90%, and an 8% narrowing of net loss to $(886K). Nine-month revenue rose 14% to $5.5M, working capital reached $3.1M, and the company retired its remaining note.

Financial results
6 source passages
Q3’26 license fee revenue rose 39% to $1.3M, reflecting continued growth in its base of annual recurring software revenue. Q3’26 gross margin improved to 90% vs. 77% in Q3’25, reflecting the increase in high-margin license fees as a percentage of total revenue. Q3’26 net loss narrowed 8% to $(886K) vs. $(965K) in Q3’25. 9M’26 revenues grew 14% to $5.5M, gross margin improved to 86% from 77%, and net loss improved 42% to $(1.7M) vs. $(2.9M) in 9M’25. Working capital improved to $3.1M at the close of Q3’26, from $1.4M at year-end 2025. BIO-key retired its remaining note in Q3’26. Open the document at this passage
Oct 30
Current report 8-K
Stockholders approve warrant-share issuance of up to 1,236,668 shares

On October 30, 2026, Bio Key International, Inc. stockholders approved issuing up to 1,236,668 common shares upon exercise of warrants issued in the August 10, 2026 warrant inducement transaction.

Shareholder vote results
2 source passages
At the reconvened Annual Meeting held on October 30, 2026, the Company’s stockholders approved Proposal 4 as set forth below. Proposal 4, which sought stockholder approval, for purposes of complying with Nasdaq Listing Rule 5635(d), of the issuance of up to 1,236,668 shares of the Company’s common stock upon the exercise of warrants issued in the Company’s August 10, 2026 warrant inducement transaction, was approved, and the final voting results were as follows: Open the document at this passage
Oct 30
Registration statement S-1/A
Resale registration covers shares issuable upon warrant exercise

BIO-key registered resale of up to 1,236,668 common shares issuable upon warrant exercise by Armistice Capital Master Fund Ltd.; full cash exercise would provide approximately $5,020,872.08, while sale proceeds go to the selling stockholder.

Read from the first part of this long document
4 source passages
BIO-key International, Inc. is a leading identity access management, or IAM, platform provider for the enterprise and large-scale customer and civil ID solutions. This prospectus covers the public sale of up to 1,236,668 shares of common stock issuable upon exercise of the Warrants (as defined below) by Armistice Capital Master Fund Ltd., the selling stockholder. If all Warrants exercisable for shares of common stock offered hereby are exercised for cash, we will receive aggregate gross proceeds of approximately $5,020,872.08. All of the proceeds from the sale of the shares covered by this prospectus will be received by the selling stockholder. Open the document at this passage
Oct 9
Registration statement S-1
Registration statement

BIO-key International, Inc. registered the resale of up to 1,236,668 shares issuable upon warrant exercise. Warrants have a $4.06 exercise price, require stockholder approval, and would generate $5,020,872.08 in gross proceeds if exercised for cash.

Read from the first part of this long document
Oct 6
Current report 8-K Events of Oct 2
Shareholder vote results, Other events

BIO-KEY INTERNATIONAL, INC. stockholders approved board elections, ratification of M&K CPAs, PLLC, and advisory executive compensation; voting remains open on approval of up to 1,236,668 shares upon warrant exercise, with the meeting reconvening October 30, 2026.

Oct 6
Proxy statement DEFA14A
Proxy statement

Bio Key International Inc stockholders approved Proposals 1, 2 and 3 on October 2, 2026 and adjourned consideration of Proposal 4, which seeks approval to issue up to 1,236,668 common shares upon exercise of warrants.

Oct 2
Current report 8-K Events of Sep 29
Entered into a material agreement, Unregistered sale of equity

BIO-key International, Inc. entered four Exchange Agreements with Streeterville Capital, LLC on September 29, 2026, exchanging four partitioned promissory notes totaling $416,315.80 for 247,805 common shares, fully paying the Original Note.

Sep 8
Current report 8-K Events of Sep 3
Other events AI summary on its way
Aug 14
Proxy statement PRE 14A Meeting Sep 3, 2026
Proxy statement AI summary on its way
Aug 13
Quarterly report 10-Q FY2026 Q2, ended Jun 30
Quarterly report for FY2026 Q2 AI summary on its way
Revenue $1.92M ▲ 13.1% Net loss $576.85K
Jul 24
Proxy statement DEF 14A Meeting Sep 3, 2026
Proxy statement AI summary on its way
Jun 22
Quarterly report 10-Q FY2026 Q1, ended Mar 31
Quarterly report for FY2026 Q1 AI summary on its way
Revenue $2.15M ▲ 33.5% Net loss $205.04K
Jun 12
Annual report 10-K FY2025, ended Dec 31
Annual report for FY2025 AI summary on its way
Revenue $5.94M ▼ 14.3% Net loss $7.16M
Mar 16
Proxy statement DEF 14A Meeting Apr 20, 2026
Proxy statement AI summary on its way
Mar 6
Proxy statement PRE 14A Meeting Apr 20, 2026
Proxy statement AI summary on its way
2025
Showing 1–50 of 195 documents
Key facts CIK 1019034 CUSIP 09060C606 13F (30d) 6 filings 6 filers Visit website Investor relations